Novel compounds in preclinical/early clinical development for the treatment of HIV infections

Reviews in Medical Virology

Volumn 10, Issue 4, 2000, Pages 255-277

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 8 DIFLUOROMETHOXY 1 ETHYL 6 FLUORO 1,4 DIHYDRO 7 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 4 OXO 3 QUINOLINECARBOXYLIC ACID; ABACAVIR; ADEFOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; BETULIC ACID; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CICHORIC ACID; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EM 2487; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; INTEGRASE INHIBITOR; LAMIVUDINE; MESSENGER RNA; N (6 AMINOHEXYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N BENZYLGLYCYL N (3 GUANIDINOPROPYL)GLYCYL DEXTRO LYSYL DEXTRO LYSYL DEXTRO ARGINYL DEXTRO PROLINAMIDE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NEVIRAPINE; PHOSPHORAMIDIC ACID DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; UREA DERIVATIVE; VIRUS DNA; VIRUS ENVELOPE PROTEIN; ZALCITABINE; ZIDOVUDINE; ZINC FINGER PROTEIN; ZINTEVIR;

CLINICAL TRIAL; DNA INTEGRATION; DRUG TARGETING; ENZYME ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PROVIRUS; REVIEW; RNA TRANSCRIPTION; VIRUS ADSORPTION; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS REPLICATION;

EID: 0033927489     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1654(200007/08)10:4<255::AID-RMV282>3.0.CO;2-6     Document Type: Review

References (165)

1. Tavel JA, Miller KD, Masur H. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors. Clin Infect Dis 1999; 28: 643-676.
2. Henry K, Erice A, Tierney C, et al. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug and alternating drug) for the treatment of advanced AIDS. J AIDS Hum Retrovirol 1998; 19: 339-349.
3. Bisset LR, Cone RW, Huber W, et al. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. AIDS 1998; 12: 2115-2123.
4. Harris M, Patenaude P, Cooperberg P, et al. Correlation of virus load in plasma and lymph node tissue in human immunodeficiency virus infection. J Infect Dis 1997; 176: 1388-1392.
5. Pakker NG, Kroon EDMB, Roos MTL, et al. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. AIDS 1999; 13: 203-212.
6. Zaunders JJ, Cunningham PH, Kelleher AD, et al. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viraemia. J Infect Dis 1999; 180: 320-329.
7. Woods II ML, MacGinley R, Eisen DP, Allworth AM. HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS 1998; 12: 1491-1494.
8. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 1998; 12: 1459-1464.
9. Albrecht H, Hoffmann C, Degen O, et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 1998; 12: 1149-1154.
10. Miralles P, Berenguer J, García de Viedma D, et al. Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy. AIDS 1998; 12: 2467-2472.
11. Dworkin MS, Wan P-CT, Hanson DL, et al. Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. J Infect Dis 1999; 180: 621-625.
12. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998; 177: 1080-1083.
13. Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Reed JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998; 177: 1182-1187.
14. O'Sullivan CE, Drew WL, McMullen DJ, et al. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy. J Infect Dis 1999; 180: 847-849.
15. Deayton J, Mocroft A, Wilson P, Emery VC, Johnson MA, Griffiths PD. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy. AIDS 1999; 13: 1203-1206.
16. Casado JL, Perez-Elías MJ, Martí-Belda P, et al. Improved outcome of cytomegalovirus retinitis in AIDS patients after introduction of protease inhibitors. J AIDS Hum Retrovirol 1998; 19: 130-134.
17. Walsh JC, Jones CD, Barnes EA, Gazzard BG, Mitchell SM. Increased survival in AIDS patients with cytomegalovirus retinitis treated with combi-nation antiretroviral therapy including HIV protease inhibitors. AIDS 1998; 12: 613-618.
18. Whitley RJ, Jacobson MA, Friedberg DN, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy. Arch Intern Med 1998; 158: 957-969.
19. Jouan M, Katlama C. Management of CMV retinitis in the era of highly active antiretroviral therapy. Int J Antimicrob Agents 1999; 13: 1-7.
20. + T cells. Science 1999; 286: 1353-1357.
21. Witvrouw M, De Clercq E. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen Pharmac 1997; 29: 497-511.
22. Gallaher WR, Ball JM, Garry RF, Martin-Amedee AM, Montelaro RC. A general model for the surface glycoproteins of HIV and other retroviruses. AIDS Res Hum Retrovir 1995; 11: 191-202.
23. Shukla D, Liu J, Blaiklock P, et al. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 1999; 99: 13-22.
24. Rusconi S, Moonis M, Merrill DP, et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 1996; 40: 234-236.
25. Yamamoto N, Schols D, De Clercq E, et al. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents. Mol Pharmacol 1992; 42: 1109-1117.
26. Ojwang JO, Buckheit RW, Pommier Y, et al. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1995; 39: 2426-2435.
27. Jing N, Hogan ME. Structure-activity of tetrad-forming oligonucleotides as a potent anti-HIV therapeutic drug. J Biol Chem 1998; 273: 34992-34999.
28. Jing N, De Clercq E, Rando RF, et al. Stability-activity relationships of a family of G-tetrad forming oligonucleotides as potent HIV inhibitors: a basis for anti-HIV drug design. J Biol Chem 2000; 275: 3421-3430.
29. Kuipers ME, v d Berg M, Swart PJ, et al. Mechanism of anti-HIV activity of succinylated human serum albumin. Biochem Pharmacol 1999; 57: 889-898.
30. Cherepanov P, Esteí JA, Rando RF, et al. Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1. Mol Pharmacol 1997; 52: 771-780.
31. Esteí JA, Cabrera C, Schols D, et al. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (zintevir). Mol Pharmacol 1998; 53: 340-345.
32. Esteí JA, Schols D, De Vreese K, et al. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol Pharmacol 1997; 52: 98-104.
33. Mori H, Otake T, Oishi I, Kurimura T. Characterization of human immunodeficiency virus type 1 resistant to modified cyclodextrin sulphate (mCDS71) in vitro. Antiviral Chem Chemother 1999; 10: 15-21.
34. Cabrera C, Witvrouw M, Gutieírrez A, et al. Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4. AIDS Res Hum Retrovir 1999; 15: 1535-1543.
35. Berson JF, Long D, Doranz BJ, Rucker J, Jirik FR, Doms RW. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 1996; 70: 6288-6295.
36. Doranz BJ, Lu ZH, Rucker J, et al. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J Virol 1997; 71: 6305-6314.
37. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-445.
38. Menten P, Struyf S, Schutyser E, et al. The LD78β isoform of MIP-1α is the most potent CCR5 agonist and HIV-1-inhibiting chemokine. J Clin Invest 1999; 104: R1-R5.
39. Nibbs RJB, Yang J, Landau NR, Mao J-H, Graham GJ. LD78β, a non-allelic variant of human MIP-1α (LD78α), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem 1999; 274: 17478-17483.
40. Baba M, Nishimura O, Kanzaki N, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 1999; 96: 5698-5703.
41. Schols D, Struyf S, Van Damme J, Esteí JA, Henson G, De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997; 186: 1383-1388.
42. Murakami T, Nakajima T, Koyanagi Y, et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997; 186: 1389-1393.
43. Doranz BJ, Grovit-Ferbasi K, Sharron MP, et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997; 186: 1395-1400.
44. 7]-polyphemusin II). Bioorg Med Chem 1998; 6: 231-238.
45. Arakaki R, Tamamura H, Premanathan M, et al. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 1999; 73: 1719-1723.
46. De Clercq E, Yamamoto N, Pauwels R, et al. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci U S A 1992; 89: 5286-5290.
47. De Clercq E, Yamamoto N, Pauwels R, et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother 1994; 38: 668-674.
48. Schols D, Esteí J, Henson G, De Clercq E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 1997; 35: 147-156.
49. Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Med 1998; 4: 72-77.
50. De Vreese K, Reymen D, Griffin P, et al. The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antiviral Res 1996; 29: 209-219.
51. Esteí JA, De Vreese K, Witvrouw M, et al. Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. Antiviral Res 1996; 29: 297-307.
52. De Vreese K, Kofler-Mongold V, Leutgeb C, et al. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J Virol 1996; 70: 689-696.
53. De Vreese K, Van Nerum I, Vermeire K, Anneí J, De Clercq E. Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120. Antimicrob Agents Chemother 1997; 41: 2616-2620.
54. Schols D, Esteí J, Cabrera C, De Clercq E. T-Cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1α contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J Virol 1998; 72: 4032-4037.
55. Labrosse B, Brelot A, Heveker N, et al. Determi-nants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol 1998; 72: 6381-6388.
56. Egberink HF, De Clercq E, Van Vliet ALW, et al. Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication. J Virol 1999; 73: 6346-6352.
57. Esteí JA, Cabrera C, Blanco J, et al. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J Virol 1999; 73: 5577-5585.
58. Datema R, Rabin L, Hincenbergs M, et al. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob Agents Chemother 1996; 40: 750-754.
59. Sodroski JG. HIV-1 entry inhibitors in the side pocket. Cell 1999; 99: 243-246.
60. Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999; 99: 103-115.
61. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retrovir 1993; 9: 1051-1053.
62. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994; 91: 9770-9774.
63. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998; 72: 986-993.
64. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med 1998; 4: 1302-1307.
65. Pilcher CD, Eron JJ, Ngo L, et al. Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual. AIDS 1999; 13: 2171-2173.
66. Helynck G, Dubertret C, Mayaux J-F, Leboul J. Isolation of RP 71955, a new anti-HIV-1 peptide secondary metabolite. J Antibiotics 1993; 46: 1756-1757.
67. Freíchet D, Guitton JD, Herman F, et al. Solution structure of RP 71955, a new 21 amino acid tricyclic peptide active against HIV-1 virus. Biochemistry 1994; 33: 42-50.
68. Constantine KL, Friedrichs MS, Detlefsen D, et al. High-resolution solution structure of siamycin II: novel amphipathic character of a 21-residue peptide that inhibits HIV fusion. J Biomol NMR 1995; 5: 271-286.
69. Chokekijchai S, Kojima E, Anderson S, et al. NP-06: a novel anti-human immunodeficiency virus poly-peptide produced by a Streptomyces species. Antimicrob Agents Chemother 1995; 39: 2345-2347.
70. Nakashima H, Ichiyama K, Inazawa K, et al. FR901724, a novel anti-human immunodeficiency virus (HIV) peptide produced by Streptomyces, shows synergistic antiviral activities with HIV protease inhibitor and 2',3'-dideoxynucleosides. Biol Pharm Bull 1996; 19: 405-412.
71. Lin P-F, Samanta H, Bechtold CM. Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor. Antimicrob Agents Chemother 1996; 40: 133-138.
72. Mayaux J-F, Bousseau A, Pauwels R, et al. Triter-pene derivatives that block entry of human immunodeficiency virus type 1 into cells. Proc Natl Acad Sci U S A 1994; 91: 3564-3568.
73. Labrosse B, Pleskoff O, Sol N, Jones C, Henin Y, Alizon M. Antiviral and resistance studies of RPR103611, an inhibitor of HIV replication. In International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication: June 25-28 1997: St Petersburg, Florida, USA. Antiviral Ther. 21, abstract 33. International Medical Press: London.
74. Rice WG, Turpin JA, Arthur LO, Henderson LE. Highly conserved retroviral zinc fingers as targets for HIV-1 therapeutic management. Int Antiviral News 1995; 3: 87-89.
75. Rice WG, Schaeffer CA, Harten B, et al. Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds. Nature 1993; 361: 473-475.
76. Rice WG, Schaeffer CA, Graham L, et al. The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes. Proc Natl Acad Sci USA1993; 90: 9721-9724.
77. Rice WG, Supko JG, Malspeis L, et al. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 1995; 270: 1194-1197.
78. Turpin JA, Terpening SJ, Schaeffer CA, et al. Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles. J Virol 1996; 70: 6180-6189.
79. Witvrouw M, Balzarini J, Pannecouque C, et al. SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus. Antimicrob Agents Chemother 1997; 41: 262-268.
80. Rice WG, Baker DC, Schaeffer CA, et al. Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob Agents Chemother 1997; 41: 419-426.
81. Vandevelde M, Witvrouw M, Schmit JC, Sprecher S, De Clercq E, Tassignon J-P. ADA, a potential anti-HIV drug. AIDS Res Hum Retrovir 1996; 12: 567-568.
82. Rice WG, Turpin JA, Huang M, et al. Azodicarbon-amide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nature Med 1997; 3: 341-345.
83. Jones IM, Morikawa Y. The molecular basis of HIV capsid assembly. Rev Med Virol 1998; 8: 87-95.
84. Turpin JA, Schaeffer CA, Terpening SJ, Graham L, Bu M, Rice WG. Reverse transcription of human immunodeficiency virus type 1 is blocked by retroviral zinc finger inhibitors. Antiviral Chem Chemother 1997; 8: 60-69.
85. Huang M, Maynard A, Turpin JA, et al. Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins. J Med Chem 1998; 31: 1371-1381.
86. Tassignon J, Ismaili J, Le Moine A, et al. Azodi-carbonamide inhibits T-cell responses in vitro and in vivo. Nature Med 1999; 5: 947-950.
87. De Clercq E. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J Med Chem 1995; 38: 2491-2517.
88. Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, De Clercq E. HPMPC (cidofovir), PMEA (adefo-vir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem Chemother 1997; 8: 1-23.
89. De Muys J-M, Gourdeau H, Nguyen-Ba N, et al. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. Antimicrob Agents Chemother 1999; 43: 1835-1844.
90. Gu Z, Wainberg MA, Nguyen-Ba N, et al. Mechanism of action and in vitro activity of 1',3'-dioxola-nylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob Agents Chemother 1999; 43: 2376-2383.
91. Uchida H, Kodama EN, Yoshimura K, et al. In vitro anti-human immunodeficiency virus activities of Z-and E-methylenecyclopropane nucleoside analogues and their phosphoro-L-alaninate die-sters. Antimicrob Agents Chemother 1999; 43: 1487-1490.
92. Yoshimura K, Feldman R, Kodama E, et al. In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues. Antimicrob Agents Chemother 1999; 43: 2479-2483.
93. Meyer PR, Matsuura SE, So AG, Scott WA. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci U S A 1998; 95: 13471-13476.
94. Meyer PR, So AG, Scott WA. Removal of chain terminators from blocked primers by HIV-1 reverse transcriptase: implications for drug resistance. Int Antiviral News 1999; 7: 124-127.
95. Perigaud C, Aubertin A-M, Benzaria S, et al. Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3'-azido-2',3'-dideoxythymidine. Biochem Pharmacol 1994; 48: 11-14.
96. McGuigan C, Tsang H-W, Cahard D, et al. Phosphoramidate derivatives of d4T as inhibitors of HIV: the effect of amino acid variation. Antiviral Res 1997; 35: 195-204.
97. Siddiqui AQ, Ballatore C, McGuigan C, De Clercq E, Balzarini J. The presence of substituents on the aryl moiety of the aryl phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell culture: a structure-activity relationship. J Med Chem 1999; 42: 393-399.
98. Siddiqui AQ, McGuigan C, Ballatore C, et al. Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSAR. J Med Chem 1999; 42: 4122-4128.
99. Balzarini J, Karlsson A, Aquaro S, et al. Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. Proc Natl Acad Sci U S A 1996; 93: 7295-7299.
100. Saboulard D, Naesens L, Cahard D, et al. Characterization of the activation pathway of phosphoramidate triester prodrugs of stavu-dine and zidovudine. Mol Pharmacol 1999; 56: 693-704.
101. Meier C, Lorey M, De Clercq E, Balzarini J. Cyclic saligenyl phosphotriesters of 2',3'-dideoxy-2',3'-didehydrothymidine (d4T)-a new pro-nucleotide approach. Bioorg Med Chem Lett 1997; 7: 99-104.
102. Meier C, Knispel T, De Clercq E, Balzarini J. ADA-bypass by lipophilic cycloSal-ddAMP pronucleotides. A second example of the efficiency of the cycloSal-concept. Bioorg Med Chem Lett 1997; 7: 1577-1582.
103. Meier C, Lorey M, De Clercq E, Balzarini J. cycl Sal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system. J Med Chem 1998; 41: 1417-1427.
104. Meier C, Knispel T, De Clercq E, Balzarini J. cycloSal-pronucleotides of 2',3'-dideoxyadenosine and 2',3'-dideoxy-2',3'-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system. J Med Chem 1999; 42: 1604-1614.
105. Meier C, Knispel T, Marquez VE, Siddiqui MA, De Clercq E, Balzarini J. cycloSal-pronucleotides of 2'-fluoro-ara-and 2'-fluoro-ribo-2',3'-dideoxyadeno-sine as a strategy to bypass a metabolic blockade. J Med Chem 1999; 42: 1615-1624.
106. De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 1998; 38: 153-179.
107. Ren J, Esnouf RM, Hopkins AL, et al. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry 1998; 37: 14394-14403.
108. Chimirri A, Grasso S, Molica C, et al. Structural features and anti-human immunodeficiency virus (HIV) activity of the isomers of 1-(2',6'-diflu-orophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Antiviral Chem Chemother 1997; 8: 363-370.
109. Chimirri A, Grasso S, Monforte AM, et al. Synthesis, structure and in vitro anti-human immunodeficiency virus activity of novel 3-methyl-1H,3H-thiazolo[3,4-a]benzimidazoles. Antiviral Chem Chemother 1998; 9: 431-438.
110. Chimirri A, Grasso S, Monforte P, et al. Synthesis and biological activity of novel 1H,3H-thiazolo-[3,4-a]benzimidazoles: non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. Antiviral Chem Chemother 1999; 10: 211-217.
111. Hsiou Y, Das K, Ding J, et al. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J Mol Biol 1998; 284: 313-323.
112. Borkow G, Arion D, Wainberg MA, Parniak MA. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43: 259-263.
113. Witvrouw M, Pannecouque C, Van Laethem K, Desmyter J, De Clercq E, Vandamme A-M. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 1999; 13: 1477-1483.
114. Witvrouw M, Arranz ME, Pannecouque C, et al. 1,1, 3-Trioxo-2H, 4H-thieno[3, 4-e][1,2, 4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity. Antimicrob Agents Chemother 1998; 42: 618-623.
115. Arranz E, Diaz JA, Ingate ST, et al. Novel 1,1,3-trioxo-2H,4H-thieno-[3,4-e]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication. J Med Chem 1998; 41: 4109-4117.
116. th International Conference on Antiviral Research, Jerusalem, Israel, March 21-25, 1999. Antiviral Res. 1999; 41: A48.
117. Fujiwara T, Sato A, El-Farrash M, et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1998; 42: 1340-1345.
118. Fujiwara T, Sato A, Patick AK, Potts KE. In vitro antiviral activity and resistance profile of AG1549 (S-1153), a new non-nucleoside inhibitor of HIV-1 reverse transcriptase. Int Antiviral News 1999; 7: 18-20.
119. Wishka DG, Graber DR, Kopta LA, et al. (-)-6-Chloro-2-[(1-furo[2,3-c]pyridin-5-yl-ethyl)thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor. J Med Chem 1998; 41: 1357-1360.
120. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Rational design of N-[2-(2,5-dimethoxyphenyl-ethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus. Bioorg Med Chem Lett 1999; 9: 1593-1598.
121. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus. Antiviral Chem Chemother 1999; 10: 233-240.
122. Taylor DL, Ahmed PS, Chambers P, et al. Pyrido[1,2-a]indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Antiviral Chem Chemother 1999; 10: 79-86.
123. Corbett JW, Ko SS, Rodgers JD, et al. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43: 2893-2897.
124. Pommier Y, Pilon AA, Bajaj K, Mazumder A, Neamati N. HIV-1 integrase as a target for antiviral drugs. Antiviral Chem Chemother 1997; 8: 463-483.
125. Eich E, Pertz H, Kaloga M, et al. (-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase. J Med Chem 1996; 39: 86-95.
126. Neamati N, Mazumder A, Sunder S, Owen JM, Schultz RJ, Pommier Y. 2-Mercaptobenzene-sulphonamides as novel inhibitors of human immunodeficiency virus type 1 integrase and replication. Antiviral Chem Chemother 1997; 8: 485-495.
127. Neamati N, Hong H, Sunder S, Milne GWA, Pommier Y. Potent inhibitors of human immunodeficiency virus type 1 integrase: identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors. Mol Pharmacol 1997; 52: 1041-1055.
128. Hong H, Neamati N, Winslow HE, et al. Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Antiviral Chem Chemother 1998; 9: 461-472.
129. Neamati N, Mazumder A, Sunder S, et al. Highly potent synthetic polyamides, bisdistamycins, and lexitropsins as inhibitors of human immunodeficiency virus type 1 integrase. Mol Pharmacol 1998; 54: 280-290.
130. Desideri N, Sestili I, Stein ML, Tramontano E, Corrias S, La Colla P. Synthesis and anti-human immunodeficiency virus type 1 integrase activity of hydroxybenzoic and hydroxycinnamic acid flavon-3-yl esters. Antiviral Chem Chemother 1998; 9: 497-509.
131. Artico M, Di Santo R, Costi R, et al. Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling. J Med Chem 1998; 41: 3948-3960.
132. Farnet CM, Wang B, Hansen M, et al. Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism. Antimicrob Agents Chemother 1998; 42: 2245-2253.
133. Robinson WE Jr, Reinecke MG, Abdel-Malek S, Jia Q, Chow SA. Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc Natl Acad Sci U S A 1996; 93: 6326-6331.
134. Robinson WE Jr. L-Chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of zidovudine plus a protease inhibitor (AG1350). Antiviral Res 1998; 39: 101-111.
135. King PJ, Robinson WE Jr. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J Virol 1998; 72: 8420-8424.
136. Mazumder A, Raghavan K, Weinstein J, Kohn KW, Pommier Y. Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem Pharmacol 1995; 49: 1165-1170.
137. Robinson WE Jr, Cordeiro M, Abdel-Malek S, et al. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase. Mol Pharmacol 1996; 50: 846-855.
138. Mazumder A, Neamati N, Sunder S, et al. Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. J Med Chem 1997; 40: 3057-3063.
139. McDougall B, King PJ, Wu BW, et al. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 1998; 42: 140-146.
140. Pluymers W, Pannecouque C, Fikkert V, et al. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol Pharmacol 2000; submitted for publication.
141. Daelemans D, Vandamme A-M, De Clercq E. Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. Antiviral Chem Chemother 1999; 10: 1-14.
142. Watson K, Edwards RJ. HIV-1 trans-activating (Tat) protein. Both a target and a tool in therapeutic approaches. Biochem Pharmacol 1999; 58: 1521-1528.
143. Watson K, Gooderham NJ, Davies DS, Edwards RJ. Interaction of the transactivating protein HIV-1 Tat with sulphated polysaccharides. Biochem Pharmacol 1999; 57: 775-783.
144. Baba M, Okamoto M, Makino M, et al. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquino-line derivatives. Antimicrob Agents Chemother 1997; 41: 1250-1255.
145. Turpin JA, Buckheit RW Jr, Derse D, et al. Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription. Antimicrob Agents Chemother 1998; 42: 487-494.
146. Baba M, Okamoto M, Kawamura M, et al. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroqui-noline derivatives. Mol Pharmacol 1998; 53: 1097-1103.
147. Okamoto M, Okamoto T, Baba M. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells. Antimicrob Agents Chemother 1999; 43: 492-497.
148. Baba M, Okamoto M, Takeuchi H. Inhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces species. Antimicrob Agents Chemother 1999; 43: 2350-2355.
149. Kashanchi F, Sadaie MR, Brady JN. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs. Virology 1997; 227: 431-438.
150. Choudhury I, Wang J, Rabson AB, et al. Inhibition of HIV-1 replication by a Tat RNA-binding domain peptide analog. J AIDS Hum Retrovirol 1998; 17: 104-111.
151. Hamy F, Felder ER, Heizmann G, et al. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci USA1997; 94: 3548-3553.
152. Daelemans D, Schols D, Witvrouw M, et al. A second target for the peptoid Tat/trans-activation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol Pharmacol 2000; 57: 116-124.
153. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338: 1281-1292.
154. Molla A, Granneman GR, Sun E, Kempf DJ. Recent developments in HIV protease inhibitor therapy. Antiviral Res 1998; 39: 1-23.
155. Thaisrivongs S, Tomich PK, Watenpaugh KD, et al. Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem 1994; 37: 3200-3204.
156. Skulnick HI, Johnson PD, Howe WJ, et al. Structure-based design of sulfonamide-substituted nonpeptidic HIV protease inhibitors. J Med Chem 1995; 38: 4968-4971.
157. Lam PYS, Ru Y, Jadhav PK, et al. Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas. J Med Chem 1996; 39: 3514-3525.
158. Hodge CN, Aldrich PE, Bacheler LT, et al. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and x-ray crystal structure of DMP 450. Chem Biol 1996; 3: 301-314.
159. Jadhav PK, Woerner FJ, Lam PYS, et al. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies. J Med Chem 1998; 41: 1446-1455.
160. Bold G, Fässler A, Capraro H-G, et al. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J Med Chem 1998; 41: 3387-3401.
161. Fors KS, Gage JR, Heier RF, et al. A convergent, scalable synthesis of HIV protease inhibitor PNU-140690. J Org Chem 1998; 63: 7348-7356.
162. Turner SR, Strohbach JW, Tommasi RA, et al. Tipranavir (PNU-140690): a potent, orally bioavail-able nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 1998; 41: 3467-3476.
163. Poppe SM, Slade DE, Chong K-T, et al. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 1997; 41: 1058-1063.
164. 2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold. J Med Chem 1998; 41: 3782-3792.
165. Hoetelmans RMW. Tipranavir. Curr Opin Anti-Infect Invest Drugs 1999; 1: 241-245.